PMSF (Synonyms: Phenylmethylsulfonyl fluoride; Benzylsulfonyl fluoride)

Name: PMSF
Brand: MedChemExpress
SKU: HY-B0496
Rating: 5.0 (146 reviews)

Cat. No.: HY-B0496 Purity: 99.32%: Data Sheet
COA

SDS
Handling Instructions
FAQs
Technical Support

PMSF (Phenylmethylsulfonyl fluoride) is a nonspecific and irreversible serine proteases inhibitor. PMSF inhibits some thiol proteases, non-protease enzymes, and acetylcholinesterase. PMSF can be used to prepare protein extracts from tissue and cell lysates.

연구목적의 판매만을 진행합니다. 환자를 대상으로 한 판매는 하지 않습니다.

PMSF 화학구조

CAS No. : 329-98-6

사이즈	재고	수량
Solid + Solvent (Highly Recommended)
10 mM * 1 mL in DMSO ready for reconstitution	해외재고보유	Estimated Time of Arrival: December 31
Solution
10 mM * 1 mL in DMSO	해외재고보유	Estimated Time of Arrival: December 31
Solid
100 mg	해외재고보유	Estimated Time of Arrival: December 31
500 mg	해외재고보유	Estimated Time of Arrival: December 31
1 g	견적 받기
5 g	견적 받기

or 대량구매 문의

* 장바구니에 담기 전 물품의 수량을 선택해 주십시오.

This product is a controlled substance and not for sale in your territory.

고객리뷰

Based on 146 publication(s) in Google Scholar

146 Publications Citing Use of MCE PMSF

Featured Recommendations

•Related Screening Libraries:

•Related Small Molecules:

•Related Proteins:

View All Cathepsin Isoform Specific Products:

View All Isoforms

Cathepsin B Cathepsin C Cathepsin D Cathepsin E Cathepsin K Cathepsin L Cathepsin S

Biological Activity
Protocol
순도&문서
References
고객리뷰

제품 설명

Cellular Effect

Cell Line	Type	Value	Description	References
Neutrophil	IC₅₀	109518.5 1 Compound: PMSF	Antiinflammatory activity in human neutrophils assessed as inhibition of FMLP-induced neutrophil elastase release treated 5 mins before FMLP challenge measured after 10 mins Antiinflammatory activity in human neutrophils assessed as inhibition of FMLP-induced neutrophil elastase release treated 5 mins before FMLP challenge measured after 10 mins	[PMID: 20417587]
Neutrophil	IC₅₀	35.24 6 Compound: Phenylmethylsulfonyl fluoride	Antiinflammatory activity against human neutrophils assessed as inhibition of fMLP/CB-induced elastase release Antiinflammatory activity against human neutrophils assessed as inhibition of fMLP/CB-induced elastase release	[PMID: 19128011]
Neutrophil	IC₅₀	130.9 3 Compound: PMSF	Antiinflammatory activity in fMLP/cytochalasin B-stimulated human neutrophils assessed as inhibition of elastase release after 5 mins Antiinflammatory activity in fMLP/cytochalasin B-stimulated human neutrophils assessed as inhibition of elastase release after 5 mins	[PMID: 19110343]
Neutrophil	IC₅₀	130.9 3 Compound: PMSF	Antiinflammatory activity in fMLP/cytochalasin B-stimulated human neutrophils assessed as inhibition of elastase release after 5 mins Antiinflammatory activity in fMLP/cytochalasin B-stimulated human neutrophils assessed as inhibition of elastase release after 5 mins	[PMID: 19110343]
Neutrophil	IC₅₀	131 6 Compound: PMSF	Antiinflammatory activity in human neutrophils assessed as inhibition of fMLP/CB-induced elastase release using MeO-Suc-Ala-Ala-Pro-Val-MC as substrate by spectrophotometry Antiinflammatory activity in human neutrophils assessed as inhibition of fMLP/CB-induced elastase release using MeO-Suc-Ala-Ala-Pro-Val-MC as substrate by spectrophotometry	[PMID: 22595179]
Neutrophil	IC₅₀	35.68 3 Compound: phenylmethylsulfonyl fluoride	Antiinflammatory activity in human neutrophils assessed as inhibition of fMet-Leu-Phe/Cytochalasin B-induced elastase release at 10 ug/mL Antiinflammatory activity in human neutrophils assessed as inhibition of fMet-Leu-Phe/Cytochalasin B-induced elastase release at 10 ug/mL	[PMID: 18163582]
Neutrophil	IC₅₀	22.8 6 Compound: PMSF	Antiinflammatory activity in human neutrophils assessed as inhibition of FMLP/CB-induced elastase release incubated for 5 mins prior to FMLP/CB-challenge by spectrophotometry Antiinflammatory activity in human neutrophils assessed as inhibition of FMLP/CB-induced elastase release incubated for 5 mins prior to FMLP/CB-challenge by spectrophotometry	[PMID: 22413887]
Neutrophil	IC₅₀	109518 1 Compound: PMSF	Antiinflammatory activity in human neutrophils assessed as inhibition of FMLP-induced neutrophil elastase release treated 5 mins before FMLP challenge measured after 10 mins Antiinflammatory activity in human neutrophils assessed as inhibition of FMLP-induced neutrophil elastase release treated 5 mins before FMLP challenge measured after 10 mins	[PMID: 20417587]
Neutrophil	IC₅₀	203.5 3 Compound: phenylmethylsulfonyl fluoride	Antiinflammatory activity in human neutrophils assessed as inhibition of fMet-Leu-Phe/Cytochalasin B-induced elastase release treated 5 mins before fMet-Leu-Phe/Cytochalasin B challenge Antiinflammatory activity in human neutrophils assessed as inhibition of fMet-Leu-Phe/Cytochalasin B-induced elastase release treated 5 mins before fMet-Leu-Phe/Cytochalasin B challenge	[PMID: 19203247]
Neutrophil	IC₅₀	95 3 Compound: PMSF	Inhibition of fMLP/CB-activated human neutrophil degranulation assessed as inhibition of elastase release using MeO-Suc-Ala-Ala-Pro-Val-p-nitroanilide as a substrate after 5 mins Inhibition of fMLP/CB-activated human neutrophil degranulation assessed as inhibition of elastase release using MeO-Suc-Ala-Ala-Pro-Val-p-nitroanilide as a substrate after 5 mins	[PMID: 21417387]
Neutrophil	IC₅₀	19.89 6 Compound: PMSF	Antiinflammatory activity in human neutrophils assessed as inhibition of FMLP/CB-induced elastase release Antiinflammatory activity in human neutrophils assessed as inhibition of FMLP/CB-induced elastase release	[PMID: 21106454]
Neutrophil	IC₅₀	130.9 3 Compound: PMSF	Antiinflammatory activity in fMLP/cytochalasin B-stimulated human neutrophils assessed as inhibition of elastase release after 5 mins Antiinflammatory activity in fMLP/cytochalasin B-stimulated human neutrophils assessed as inhibition of elastase release after 5 mins	[PMID: 19110343]
Neutrophil	IC₅₀	95 3 Compound: PMSF	Inhibition of FMLP/CB-stimulated elastase release in human neutrophils treated for 5 mins before FMLP/CB challenge using MeO-Suc-Ala-Ala-Pro-Val-p-nitroanilide as a substrate Inhibition of FMLP/CB-stimulated elastase release in human neutrophils treated for 5 mins before FMLP/CB challenge using MeO-Suc-Ala-Ala-Pro-Val-p-nitroanilide as a substrate	[PMID: 21441032]
Neutrophil	IC₅₀	22.8 6 Compound: PMSF	Antiinflammatory activity in human neutrophils assessed as inhibition of FMLP/CB-induced elastase release incubated for 5 mins prior to FMLP/CB-challenge by spectrophotometry Antiinflammatory activity in human neutrophils assessed as inhibition of FMLP/CB-induced elastase release incubated for 5 mins prior to FMLP/CB-challenge by spectrophotometry	[PMID: 22413887]
Neutrophil	IC₅₀	130.9 3 Compound: PMSF	Antiinflammatory activity in human neutrophils assessed as inhibition of fMLP/cytochalasin B-induced elastase release Antiinflammatory activity in human neutrophils assessed as inhibition of fMLP/cytochalasin B-induced elastase release	[PMID: 20036537]
Neutrophil	IC₅₀	131 6 Compound: PMSF	Antiinflammatory activity in human neutrophils assessed as inhibition of fMLP/CB-induced elastase release using MeO-Suc-Ala-Ala-Pro-Val-MC as substrate by spectrophotometry Antiinflammatory activity in human neutrophils assessed as inhibition of fMLP/CB-induced elastase release using MeO-Suc-Ala-Ala-Pro-Val-MC as substrate by spectrophotometry	[PMID: 22595179]
Neutrophil	IC₅₀	130.93 3 Compound: PMSF	Antiinflammatory activity in neutrophil assessed as inhibition of fMLP induced elastase release Antiinflammatory activity in neutrophil assessed as inhibition of fMLP induced elastase release	[PMID: 17197180]
Neutrophil	IC₅₀	131 6 Compound: PMSF	Antiinflammatory activity in human neutrophils assessed as inhibition of fMLP/CB-induced elastase release using MeO-Suc-Ala-Ala-Pro-Val-MC as substrate by spectrophotometry Antiinflammatory activity in human neutrophils assessed as inhibition of fMLP/CB-induced elastase release using MeO-Suc-Ala-Ala-Pro-Val-MC as substrate by spectrophotometry	[PMID: 22595179]
Neutrophil	IC₅₀	130.9 3 Compound: PMSF	Antiinflammatory activity in human neutrophils assessed as inhibition of fMLP/cytochalasin B-induced elastase release Antiinflammatory activity in human neutrophils assessed as inhibition of fMLP/cytochalasin B-induced elastase release	[PMID: 20036537]
Neutrophil	IC₅₀	19.89 6 Compound: PMSF	Antiinflammatory activity in human neutrophils assessed as inhibition of FMLP/CB-induced elastase release Antiinflammatory activity in human neutrophils assessed as inhibition of FMLP/CB-induced elastase release	[PMID: 21106454]
Neutrophil	IC₅₀	202.3 3 Compound: phenylmethylsulfonyl fluoride	Antiinflammatory activity in human neutrophils assessed as inhibition of fMLP/Cytochalasin B-induced elastase release Antiinflammatory activity in human neutrophils assessed as inhibition of fMLP/Cytochalasin B-induced elastase release	[PMID: 18817445]
Neutrophil	IC₅₀	202.3 3 Compound: phenylmethylsulfonyl fluoride	Antiinflammatory activity in human neutrophils assessed as inhibition of fMLP/Cytochalasin B-induced elastase release Antiinflammatory activity in human neutrophils assessed as inhibition of fMLP/Cytochalasin B-induced elastase release	[PMID: 18817445]
Neutrophil	IC₅₀	95 3 Compound: PMSF	Antiinflammatory activity in human neutrophils assessed as inhibition of fMLP/Cytochalasin B-induced elastase release Antiinflammatory activity in human neutrophils assessed as inhibition of fMLP/Cytochalasin B-induced elastase release	[PMID: 19583252]
Neutrophil	IC₅₀	203.5 3 Compound: phenylmethylsulfonyl fluoride	Antiinflammatory activity in human neutrophils assessed as inhibition of fMet-Leu-Phe/Cytochalasin B-induced elastase release treated 5 mins before fMet-Leu-Phe/Cytochalasin B challenge Antiinflammatory activity in human neutrophils assessed as inhibition of fMet-Leu-Phe/Cytochalasin B-induced elastase release treated 5 mins before fMet-Leu-Phe/Cytochalasin B challenge	[PMID: 19203247]
Neutrophil	IC₅₀	204.08 3 Compound: phenylmethylsulfonyl fluoride	Antiinflammatory activity in human neutrophils assessed as inhibition of formyl-L-methionyl-L-leucyl-L-phenylalanine/cytochalasin B-induced elastase release Antiinflammatory activity in human neutrophils assessed as inhibition of formyl-L-methionyl-L-leucyl-L-phenylalanine/cytochalasin B-induced elastase release	[PMID: 18211005]
Neutrophil	IC₅₀	130.93 3 Compound: PMSF	Antiinflammatory activity in neutrophil assessed as inhibition of fMLP induced elastase release Antiinflammatory activity in neutrophil assessed as inhibition of fMLP induced elastase release	[PMID: 17197180]
Neutrophil	IC₅₀	204.08 3 Compound: phenylmethylsulfonyl fluoride	Antiinflammatory activity in human neutrophils assessed as inhibition of formyl-L-methionyl-L-leucyl-L-phenylalanine/cytochalasin B-induced elastase release Antiinflammatory activity in human neutrophils assessed as inhibition of formyl-L-methionyl-L-leucyl-L-phenylalanine/cytochalasin B-induced elastase release	[PMID: 18211005]
Neutrophil	IC₅₀	95 3 Compound: PMSF	Inhibition of fMLP/CB-activated human neutrophil degranulation assessed as inhibition of elastase release using MeO-Suc-Ala-Ala-Pro-Val-p-nitroanilide as a substrate after 5 mins Inhibition of fMLP/CB-activated human neutrophil degranulation assessed as inhibition of elastase release using MeO-Suc-Ala-Ala-Pro-Val-p-nitroanilide as a substrate after 5 mins	[PMID: 21417387]
Neutrophil	IC₅₀	22.8 6 Compound: PMSF	Antiinflammatory activity in human neutrophils assessed as inhibition of FMLP/CB-induced elastase release incubated for 5 mins prior to FMLP/CB-challenge by spectrophotometry Antiinflammatory activity in human neutrophils assessed as inhibition of FMLP/CB-induced elastase release incubated for 5 mins prior to FMLP/CB-challenge by spectrophotometry	[PMID: 22413887]
Neutrophil	IC₅₀	95 3 Compound: PMSF	Inhibition of FMLP/CB-stimulated elastase release in human neutrophils treated for 5 mins before FMLP/CB challenge using MeO-Suc-Ala-Ala-Pro-Val-p-nitroanilide as a substrate Inhibition of FMLP/CB-stimulated elastase release in human neutrophils treated for 5 mins before FMLP/CB challenge using MeO-Suc-Ala-Ala-Pro-Val-p-nitroanilide as a substrate	[PMID: 21441032]
Neutrophil	IC₅₀	35.24 6 Compound: Phenylmethylsulfonyl fluoride	Antiinflammatory activity against human neutrophils assessed as inhibition of fMLP/CB-induced elastase release Antiinflammatory activity against human neutrophils assessed as inhibition of fMLP/CB-induced elastase release	[PMID: 19128011]
Neutrophil	IC₅₀	109518 1 Compound: PMSF	Antiinflammatory activity in human neutrophils assessed as inhibition of FMLP-induced neutrophil elastase release treated 5 mins before FMLP challenge measured after 10 mins Antiinflammatory activity in human neutrophils assessed as inhibition of FMLP-induced neutrophil elastase release treated 5 mins before FMLP challenge measured after 10 mins	[PMID: 20417587]
Neutrophil	IC₅₀	35.68 3 Compound: phenylmethylsulfonyl fluoride	Antiinflammatory activity in human neutrophils assessed as inhibition of fMet-Leu-Phe/Cytochalasin B-induced elastase release at 10 ug/mL Antiinflammatory activity in human neutrophils assessed as inhibition of fMet-Leu-Phe/Cytochalasin B-induced elastase release at 10 ug/mL	[PMID: 18163582]
Neutrophil	IC₅₀	95 3 Compound: PMSF	Antiinflammatory activity in human neutrophils assessed as inhibition of fMLP/Cytochalasin B-induced elastase release Antiinflammatory activity in human neutrophils assessed as inhibition of fMLP/Cytochalasin B-induced elastase release	[PMID: 19583252]
Neutrophil	IC₅₀	95 3 Compound: PMSF	Inhibition of fMLP/CB-activated human neutrophil degranulation assessed as inhibition of elastase release using MeO-Suc-Ala-Ala-Pro-Val-p-nitroanilide as a substrate after 5 mins Inhibition of fMLP/CB-activated human neutrophil degranulation assessed as inhibition of elastase release using MeO-Suc-Ala-Ala-Pro-Val-p-nitroanilide as a substrate after 5 mins	[PMID: 21417387]
Neutrophil	IC₅₀	95 3 Compound: PMSF	Inhibition of FMLP/CB-stimulated elastase release in human neutrophils treated for 5 mins before FMLP/CB challenge using MeO-Suc-Ala-Ala-Pro-Val-p-nitroanilide as a substrate Inhibition of FMLP/CB-stimulated elastase release in human neutrophils treated for 5 mins before FMLP/CB challenge using MeO-Suc-Ala-Ala-Pro-Val-p-nitroanilide as a substrate	[PMID: 21441032]
Neutrophil	IC₅₀	95 3 Compound: Phenylmethylsulfonyl fluoride	Inhibition of fMLF/CB-induced human Neutrophil activation assessed as reduction in superoxide anion Inhibition of fMLF/CB-induced human Neutrophil activation assessed as reduction in superoxide anion	[PMID: 37683361]

In Vitro

PMSF (2 mM) inhibits carbachol-stimulated inositol phosphate accumulation in the presence of Li⁺ by only 15%-19%. PMSF inhibition of phosphoinositide turnover is due to one or more steps following phosphoinositide breakdown^[1]. PMSF inhibits the acylation of the inositol residue of GPI intermediates in bloodstream-form T. brucei. PMSF inhibits the formation of glycolipid C but does not inhibit fatty acid remodeling in vitro. PMSF inhibits GPI acylation and ethanolamine phosphate addition in procyclic trypanosomes but not in Hela cells^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

In Vivo

PMSF (0.1 mL/10 g b.wt, i.p.) produces antinociception as indicated by the dose-responsive increase in % MPE in the tail-flick latency evaluation, but fails to produce a clear dose-responsive inhibition of locomotion. Mice receiving i.p. injections of PMSF exhibit cannabinoid effects that includes antinociception, hypothermia and immobility with ED₅₀ values of 86, 224 and 206 mg/kg, respectively. PMSF (30 mg/kg) pretreatment potentiates the effects of anandamide on tail-flick response (antinociception), spontaneous activity and mobility by 5-, 10- and 8-fold, respectively^[3].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

분자량

174.19

화학식

C₇H₇FO₂S

CAS No.

329-98-6

Appearance

Solid

Color

White to off-white

SMILES

O=S(CC1=CC=CC=C1)(F)=O

선적

Room temperature in continental US; may vary elsewhere.

보관

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	6 months
	-20°C	1 month

용액&용해도

In Vitro:

DMSO : 250 mg/mL (1435.21 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

Isopropanol : 60 mg/mL (344.45 mM; Need ultrasonic)

H₂O : < 0.1 mg/mL (insoluble)

Preparing
Stock Solutions

Concentration Solvent Mass	1 mg	5 mg	10 mg

1 mM	5.7409 mL	28.7043 mL	57.4086 mL
5 mM	1.1482 mL	5.7409 mL	11.4817 mL
10 mM	0.5741 mL	2.8704 mL	5.7409 mL

View the Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

몰농도 계산기
농도 희석 계산기

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

This equation is commonly abbreviated as: C₁V₁ = C₂V₂

Concentration _(start)

Volume _(start)

Concentration _(final)

Volume _(final)

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for in vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2 mg/mL (11.48 mM); Clear solution

This protocol yields a clear solution of ≥ 2 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Protocol 2

Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 2 mg/mL (11.48 mM); Clear solution

This protocol yields a clear solution of ≥ 2 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
Protocol 3

Add each solvent one by one: 10% DMSO 90% Corn Oil
Solubility: ≥ 2 mg/mL (11.48 mM); Clear solution

This protocol yields a clear solution of ≥ 2 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.0 mg/mL) to 900 μL Corn oil, and mix evenly.

For the following dissolution methods, please prepare the working solution directly. It is recommended to prepare fresh solutions and use them promptly within a short period of time.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: Corn Oil
Solubility: 20 mg/mL (114.82 mM); Clear solution; Need ultrasonic

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage

mg/kg

Animal weight
(per animal)

Dosing volume
(per animal)

μL

Number of animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

DMSO +

Tween-80 +

Saline

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Calculation results:

Working solution concentration: mg/mL

Method for preparing stock solution: mg drug dissolved in μL DMSO (Stock solution concentration: mg/mL).

The concentration of the stock solution you require exceeds the measured solubility. The following solution is for reference only. If necessary, please contact MedChemExpress (MCE).

Method for preparing in vivo working solution for animal experiments: Take μL DMSO stock solution, add μL . μL , mix evenly, next add μL Tween 80, mix evenly, then add μL Saline.

If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.

순도&문서

Purity: 99.32%

Select Batch:

Data Sheet (280 KB) SDS (641 KB)

COA (251 KB) LCMS (87 KB) GC (305 KB)

Handling Instructions (2659 KB)

References

[1]. Sekar, M.C. and B.D. Roufogalis, Differential effects of phenylmethanesulfonyl fluoride (PMSF) on carbachol and potassium stimulated phosphoinositide turnover and contraction in longitudinal smooth muscle of guinea pig ileum. Cell Calcium, 1984. 5(3): p. [Content Brief]

[2]. Guther, M.L., W.J. Masterson, and M.A. Ferguson, The effects of phenylmethylsulfonyl fluoride on inositol-acylation and fatty acid remodeling in African trypanosomes. J Biol Chem, 1994. 269(28): p. 18694-701. [Content Brief]

[3]. Compton, D.R. and B.R. Martin, The effect of the enzyme inhibitor phenylmethylsulfonyl fluoride on the pharmacological effect of anandamide in the mouse model of cannabimimetic activity. J Pharmacol Exp Ther, 1997. 283(3): p. 1138-43. [Content Brief]

[4]. Asadi Akbarabadi E, et a. PMSF Attenuates Morphine Antinociceptive Tolerance and Dependence in Mice: Its Association with the Oxidative Stress Suppression. Iran J Pharm Res. 2021 Summer;20(3):300-309. [Content Brief]

Animal Administration
^[3]

Male ICR mice weighing 18 to 25 g are used in the assay. PMSF is dissolved in sesame oil and administered i.p. at a volume of 0.1 mL/10 g b.wt. PMSF is always administered 10 min before i.v. anandamide or vehicle injections. Mice are acclimated to the evaluation room overnight without interruption of food or water. After i.v. anandamide or vehicle administration each animal is evaluated as follows: tail-flick latency (antinociception) response at 5 min and spontaneous (locomotor) activity at 5 to 15 min; or core (rectal) temperature at 5 min and ring-immobility (catalepsy) at 5 to 10 min.

MCE 는 독립적으로 이러한 방법들의 정확성을 확인하지 않았습니다. 참고용으로만 봐주십시오.

References

[1]. Sekar, M.C. and B.D. Roufogalis, Differential effects of phenylmethanesulfonyl fluoride (PMSF) on carbachol and potassium stimulated phosphoinositide turnover and contraction in longitudinal smooth muscle of guinea pig ileum. Cell Calcium, 1984. 5(3): p. [Content Brief]

[2]. Guther, M.L., W.J. Masterson, and M.A. Ferguson, The effects of phenylmethylsulfonyl fluoride on inositol-acylation and fatty acid remodeling in African trypanosomes. J Biol Chem, 1994. 269(28): p. 18694-701. [Content Brief]

[3]. Compton, D.R. and B.R. Martin, The effect of the enzyme inhibitor phenylmethylsulfonyl fluoride on the pharmacological effect of anandamide in the mouse model of cannabimimetic activity. J Pharmacol Exp Ther, 1997. 283(3): p. 1138-43. [Content Brief]

[4]. Asadi Akbarabadi E, et a. PMSF Attenuates Morphine Antinociceptive Tolerance and Dependence in Mice: Its Association with the Oxidative Stress Suppression. Iran J Pharm Res. 2021 Summer;20(3):300-309. [Content Brief]

Complete Stock Solution Preparation Table

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg

Isopropanol / DMSO	1 mM	5.7409 mL	28.7043 mL	57.4086 mL	143.5214 mL
	5 mM	1.1482 mL	5.7409 mL	11.4817 mL	28.7043 mL
	10 mM	0.5741 mL	2.8704 mL	5.7409 mL	14.3521 mL
	15 mM	0.3827 mL	1.9136 mL	3.8272 mL	9.5681 mL
	20 mM	0.2870 mL	1.4352 mL	2.8704 mL	7.1761 mL
	25 mM	0.2296 mL	1.1482 mL	2.2963 mL	5.7409 mL
	30 mM	0.1914 mL	0.9568 mL	1.9136 mL	4.7840 mL
	40 mM	0.1435 mL	0.7176 mL	1.4352 mL	3.5880 mL
	50 mM	0.1148 mL	0.5741 mL	1.1482 mL	2.8704 mL
	60 mM	0.0957 mL	0.4784 mL	0.9568 mL	2.3920 mL
	80 mM	0.0718 mL	0.3588 mL	0.7176 mL	1.7940 mL
	100 mM	0.0574 mL	0.2870 mL	0.5741 mL	1.4352 mL

PMSF Related Classifications

Neurological Disease

Help & FAQs

Do most proteins show cross-species activity?
Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Keywords:

PMSF329-98-6Phenylmethylsulfonyl fluoride Benzylsulfonyl fluorideCathepsinSer/Thr ProteaseSerine proteasesSerine endopeptidasesThreonine proteasesInhibitorinhibitorinhibit

Please select a local distributor ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
상품명			Requested Quantity *
고객명 *			호칭
메일주소 *			전화번호 *
Department			회사명 *
City			도
Country or Region *
비고

상품명			Lot #
고객명 *			메일주소 *
전화번호			Department *
회사명 *			Country or Region *
비고

Name
이메일 *

	Sorry, but the email address you supplied was invalid.

PMSF (Synonyms: Phenylmethylsulfonyl fluoride; Benzylsulfonyl fluoride)

고객리뷰

PMSF Related Antibodies

146 Publications Citing Use of MCE PMSF

Featured Recommendations

•Related Screening Libraries:

•Related Small Molecules:

•Related Proteins:

View All Cathepsin Isoform Specific Products:

Biological Activity

Protocol

순도&문서

References

고객리뷰

PMSF Related Antibodies

몰농도 계산기

농도 희석 계산기

Complete Stock Solution Preparation Table

PMSF Related Classifications

Keywords:

최근 본 상품:

고객리뷰

Request for HNMR Report

SAFETY DATA SHEET (SDS)

Request for HNMR Report